WNK2 and central nervous system cancer: Notch1 activation was shown to promote tumor growth and drive acquired resistance to mitogen-activated protein kinase (MAPK) inhibitors in melanoma [38], as well as TMZ resistance in melanoma [39] and glioma [31,40].